…
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -552.28M | -641.08M | 314.94M | -347.69M | -236.64M |
| Net income | -557.52M | -644.09M | 313.88M | -328.70M | -236.64M |
| Selling general administrative | 237.37M | 195.29M | 157.74M | 96.39M | 47.93M |
| Gross profit | 186.22M | 162.15M | 793.31M | 66.51M | 44.52M |
| Reconciled depreciation | 11.73M | 6.48M | 6.56M | 5.26M | 4.25M |
| Ebit | -549.25M | -648.46M | 302.15M | -366.58M | -240.81M |
| Ebitda | -537.52M | -641.98M | 308.71M | -361.33M | -236.57M |
| Depreciation and amortization | 11.73M | 6.48M | 6.56M | 5.26M | 4.25M |
| Non operating income net other | 2.00M | -1.49M | -0.37M | -0.10M | 10.46M |
| Operating income | -549.25M | -648.46M | 302.15M | -366.58M | -247.03M |
| Other operating expenses | 741.55M | 822.06M | 485.03M | 427.84M | 291.55M |
| Interest expense | 16.77M | 7.38M | 12.79M | 13.73M | 0.07M |
| Tax provision | 5.24M | 3.00M | 1.06M | - | - |
| Interest income | - | - | - | 13.73M | 0.07M |
| Net interest income | -16.77M | 2.39M | 6.60M | 13.73M | -0.07M |
| Income tax expense | 5.24M | 3.00M | 1.06M | -18.99M | 10.46M |
| Total revenue | 204.04M | 180.08M | 793.74M | 66.51M | 44.52M |
| Total operating expenses | 723.74M | 804.13M | 484.60M | 427.84M | 291.55M |
| Cost of revenue | 17.81M | 17.93M | 0.42M | 331.45M | 243.62M |
| Total other income expense net | -3.03M | 7.38M | 12.79M | 18.89M | 10.46M |
| Net income from continuing ops | -557.52M | -644.09M | 313.88M | -414.21M | -281.16M |
| Net income applicable to common shares | -557.52M | -644.09M | 313.88M | -347.69M | -236.64M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1049.25M | 1349.90M | 1252.22M | 1718.39M | 707.69M |
| Other current assets | 33.35M | 35.02M | -539.47M | -655.85M | 379.44M |
| Total liab | 918.64M | 835.23M | 281.49M | 248.31M | 243.34M |
| Total stockholder equity | 130.61M | 514.68M | 970.74M | 1470.09M | 464.36M |
| Other current liab | 127.99M | -295.55M | 96.76M | 105.94M | 88.71M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.05M |
| Capital stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.05M |
| Retained earnings | -2339.94M | -1832.96M | -1275.44M | -631.36M | -945.24M |
| Other liab | - | 436.97M | 28.41M | 35.83M | 47.73M |
| Other assets | 0.00M | 26.78M | 19.81M | 569.29M | 15.39M |
| Cash | 71.29M | 119.71M | 209.95M | 684.64M | 113.94M |
| Total current liabilities | 214.92M | 183.23M | 149.76M | 130.80M | 106.48M |
| Current deferred revenue | 0.81M | 448.62M | 36.58M | 12.56M | 6.16M |
| Net debt | 702.84M | 122.74M | -98.54M | -595.03M | -17.99M |
| Short term debt | 81.41M | 27.43M | 8.09M | 7.93M | 6.82M |
| Short long term debt | 30.28M | 16.85M | - | - | - |
| Short long term debt total | 774.12M | 242.45M | 111.41M | 89.60M | 95.95M |
| Other stockholder equity | 2473.99M | 2358.02M | 2250.25M | 2106.60M | 1412.08M |
| Property plant equipment | - | 33.34M | 30.70M | 34.13M | 38.36M |
| Total current assets | 808.39M | 1046.65M | 554.02M | 927.76M | 516.79M |
| Long term investments | 84.32M | 133.48M | 557.53M | 677.87M | 64.41M |
| Net tangible assets | - | 514.68M | 1247.09M | 1470.09M | 464.36M |
| Short term investments | 639.36M | 825.28M | 267.17M | 187.21M | 369.62M |
| Net receivables | 43.18M | 36.94M | 37.03M | 25.31M | 23.41M |
| Long term debt | 208.53M | 535.28M | - | - | - |
| Inventory | 21.22M | 29.70M | 21.82M | 8.58M | -434.02M |
| Accounts payable | 4.71M | 2.73M | 8.33M | 4.37M | 4.79M |
| Accumulated other comprehensive income | -3.50M | -10.44M | -4.13M | -5.21M | -2.54M |
| Common stock total equity | - | 0.06M | 0.06M | 0.06M | 0.05M |
| Retained earnings total equity | - | -1832.96M | -1275.44M | -631.36M | -945.24M |
| Non currrent assets other | 30.65M | 26.78M | 19.81M | 11.09M | 15.39M |
| Non current assets total | 240.86M | 303.25M | 698.20M | 790.63M | 190.91M |
| Capital lease obligations | 93.68M | 103.37M | 111.41M | 89.60M | 95.95M |
| Long term debt total | - | 535.28M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -140.33M | 35.38M | -431.09M | -2.45M | -148.41M |
| Change to liabilities | 3.55M | 10.32M | 15.42M | 38.43M | 24.36M |
| Total cashflows from investing activities | -149.54M | -225.86M | -434.25M | -16.47M | -161.09M |
| Net borrowings | 553.61M | 137.79M | 137.79M | 137.79M | -1.69M |
| Total cash from financing activities | 561.81M | 50.72M | 617.76M | 340.64M | 4.45M |
| Change to operating activities | -31.99M | 1.05M | -1.35M | 31.57M | 26.01M |
| Net income | -557.52M | -644.09M | 313.88M | -347.69M | -236.64M |
| Change in cash | -90.22M | -474.69M | 570.20M | 46.17M | -331.64M |
| Begin period cash flow | 215.12M | 689.80M | 119.60M | 73.43M | 405.07M |
| End period cash flow | 124.90M | 215.12M | 689.80M | 119.60M | 73.43M |
| Total cash from operating activities | -502.28M | -298.65M | 387.04M | -278.01M | -175.01M |
| Issuance of capital stock | 0.00M | 0.00M | 582.49M | 341.04M | 6.42M |
| Depreciation | 11.73M | 6.48M | 6.56M | 5.26M | 4.25M |
| Other cashflows from investing activities | -0.29M | -258.15M | -258.15M | -2.45M | -148.41M |
| Change to inventory | -8.92M | -12.56M | -6.71M | 8.97M | -6.71M |
| Change to account receivables | 1.57M | -18.14M | -6.39M | -0.60M | 0.20M |
| Sale purchase of stock | - | - | 79.31M | 340.75M | 6.14M |
| Other cashflows from financing activities | 561.81M | 50.72M | 35.27M | -0.40M | -0.28M |
| Change to netincome | 117.39M | 95.01M | 75.95M | 54.65M | 30.53M |
| Capital expenditures | 8.92M | 261.24M | 3.16M | 14.01M | 12.68M |
| Change receivables | 1.57M | -18.14M | -6.39M | -0.60M | - |
| Cash flows other operating | -70.09M | 264.33M | -11.69M | -28.06M | 2.50M |
| Cash and cash equivalents changes | -90.01M | -473.80M | 570.54M | 46.16M | -331.64M |
| Change in working capital | -53.77M | -23.68M | -15.62M | 9.72M | 31.24M |
| Stock based compensation | 98.97M | 91.63M | 75.53M | 54.65M | 30.53M |
| Other non cash items | -1.70M | 269.64M | 6.22M | 4.99M | -4.39M |
| Free cash flow | -511.20M | -559.89M | 383.88M | -292.03M | -187.69M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
45 Sidney Street, Cambridge, MA, United States, 02139
617 374 7580
638
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey W. Albers J.D., M.B.A., MBA | Exec. Chairman | 1971 |
| Ms. Kathryn Haviland | Pres, CEO & Director | 1976 |
| Mr. Alexis A. Borisy A.M. | Co-Founder & Director | 1972 |
| Mr. Michael Landsittel | Chief Financial Officer | 1972 |
| Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer | 1971 |
| Dr. Fouad Namouni M.D. | Pres of R&D | 1969 |
| Ms. Christina Rossi | Chief Operating Officer | 1976 |
| Dr. Christopher K. Murray | Sr. VP of Technical Operations | 1963 |
| Jenna Cohen | Sr. Director & Head of Investor Relations | NA |
| Ms. Tracey L. McCain Esq. | Exec. VP, Chief Legal & Compliance Officer and Sec. | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.